R&D News | pharmaphorum

News

Boehringer moves liposarcoma drug into pivotal trial

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l

News

Celadon gets nod to start cannabis trial for pain in UK

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK.

News

Sumitomo's novel schizophrenia drug flunks phase 3 test

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of

News

Merck's challenge to Pfizer's Prevnar grows

Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

Boehringer moves liposarcoma drug into pivotal trial

Celadon gets nod to start cannabis trial for pain in UK

Sumitomo's novel schizophrenia drug flunks phase 3 test

Merck's challenge to Pfizer's Prevnar grows

AZ builds in genomic medicine with $1bn Pfizer deal

Enhertu shows survival boost in HER2+ solid tumours

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks